 |
|
Research highlights new approaches to prevent blood clots
December 08, 2008The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy will be presented in a press conference on Sunday, December 7, at 9:30 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Additional research being featured at the press conference includes studies that examine the use of three different investigational blood-thinning medications that belong to a new class of therapies called Factor Xa inhibitors. These studies evaluated the effectiveness of these medications in preventing blood clots: following major orthopedic surgery; in patients with atrial fibrillation; and in patients with deep-vein thrombosis.
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Usually, the body naturally dissolves the clot when the injury has healed; however, when a clot does not dissolve naturally, it can become extremely dangerous. Deep-vein thrombosis, a type of blood clot that typically forms in a major vein of the leg, and pulmonary embolism, which occurs when a blood clot detaches from its point of origin and travels to the lungs where it becomes wedged and prevents adequate blood flow, are known collectively as venous thromboembolism.
"Venous thromboembolism is a serious public health problem that affects almost 1 million Americans each year and is responsible for more deaths each year than breast cancer, HIV disease, and motor vehicle crashes combined," said J. Evan Sadler, MD, moderator of the press conference and Professor of Medicine and of Biochemistry and Molecular Biophysics, Washington University Medical School, St. Louis, MO. "The hematology community is committed to continuously improving treatments for these patients, and the exciting research presented today is another step forward in finding ways to eliminate this preventable leading cause of death."
Certain conditions can elevate a person's risk of clotting, including atrial fibrillation (an abnormal heart rhythm), previous heart attack, long periods of inactivity, some medications, and genetic or disease-related factors. Treatment typically consists of anticoagulants that help prevent clots from forming, medications that dissolve blood clots, catheter-directed thrombolysis (a surgical procedure where clot-dissolving medication is directed toward the blood clot), and thrombectomy, the surgical removal of a blood clot. Recognizing the deadly impact blood-clotting disorders have on millions of Americans every year, the American Society of Hematology has developed a new resource, www.bloodthevitalconnection.org, to help educate the public about these and other common blood diseases.
A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study [Abstract #6]
Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy
This study is the largest to determine that the preventive use of an antithrombotic medication can reduce the incidence of thromboembolic events in patients with cancer. It is well known that patients with cancer who receive chemotherapy are at high risk for developing deadly blood clots, but few large studies have confirmed whether the preventive use of a blood-thinning medication can reduce these events.
This multicenter, placebo-controlled, clinical outcome-based study was designed to evaluate the efficacy of nadroparin, a low-molecular-weight heparin, for the preventive treatment of thromboembolic events in cancer patients receiving chemotherapy. The primary outcome of the study was the combined occurrence of clinically overt venous or arterial thromboembolic events (i.e., deep-vein thrombosis of the lower and upper limbs, visceral and cerebral venous thrombosis, pulmonary embolism, acute myocardial infarction, ischemic stroke, acute peripheral arterial thromboembolism, and unexplained death of possible thromboembolic origin). Major bleeding was the main safety parameter.
In this study, 1,166 patients with advanced lung (279), colon (235), breast (165), ovarian (143), stomach (98), rectal (87), pancreatic (53), head and neck (36), and other cancers (54) were randomized to one of two treatment arms: once-daily subcutaneous injections of nadroparin (3,000 IU) or placebo. Twice as many patients were enrolled into the nadroparin group than the placebo group. Treatment was started on the first day of the current cycle of chemotherapy and was maintained for the overall duration of chemotherapy treatment or up to a maximum of four months.
Only 16 of the 769 patients treated with nadroparin had a thromboembolic event (2.1 percent) compared with 15 of the 381 patients (3.9 percent) in the placebo group, a 47.2 percent reduction in the risk of developing a thromboembolic event for the patients in the treatment arm. The drug also appeared to be safe as only five patients in the nadroparin group (0.7 percent) experienced a major bleeding episode, and the incidence of minor bleeding in the treatment arm was similar to that of the placebo group.
Venous thromboembolism occurred 11 times in both the nadroparin and placebo groups. Fifteen of these events occurred in patients with lung cancer (4 percent in the nadroparin arm and 8.8 percent in the placebo arm). Patients with pancreatic cancer also experienced a high overall rate of thromboembolic events (7.5 percent). While this study confirms that nadroparin reduces the incidence of thromboembolic events in cancer patients receiving chemotherapy, because of the disproportionately higher incidence of events in lung and pancreatic cancer patients, further studies should focus on patients in these two high-risk populations.
Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep-Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin [Abstract #32]
Harry Roger Buller, MD, PhD, Academic Medical Center, Amsterdam, Netherlands
This clinical trial found that six months of treatment with idrabiotaparinux, an anticoagulant and indirect Factor Xa inhibitor that links indraparinux to biotin, showed comparable efficacy to idraparinux alone with a trend toward less bleeding in patients with deep-vein thrombosis. Additionally, an infusion of avidin after the last idrabiotaparinux treatment led to a rapid reversal of the anti-Factor Xa activity, or the anticoagulant effect of the drug, which was sustained for at least five days. This study builds on previous research that showed similar efficacy and safety between once-weekly subcutaneous injections of indaparinux with standard treatment (low-molecular-weight heparin followed by a vitamin K antagonist) in the treatment of deep-vein thrombosis.
A total of 757 patients with symptomatic and confirmed deep-vein thrombosis were randomized to receive weekly subcutaneous injections of 3 mg idrabiotaparinux (385 patients) or 2.5 mg idraparinux (370 patients) for six months. The primary objective of the study was to determine whether idrabiotaparinux works in a similar manner to idraparinux (i.e., bioequipotency). The secondary objective of the study was occurrence of clinically relevant bleeding, death, or symptomatic recurrent venous thromboemolism at the end of six months of therapy.
A final objective included the reversal of the anticoagulant effect of idrabiotaparinux, as there are medically relevant instances, such as prior to surgery, when there is the need to reverse the effects of an anticoagulant. The reversal of the anticoagulant effect was measured after a 30-minute intravenous infusion of avidin (100 mg), a hen egg protein that binds with biotin to reverse the Factor Xa inhibiting activity of idrabiotaparinux. At the end of the initial six-month treatment with idrabiotaparinux, a subset of patients was re-randomized to receive avidin (those in the idrabiotaparinux arm) or placebo (those in both the idrabiotaparinux and idraparinux arms to preserve blinding). Avidin or placebo was infused between two and five hours after the last injection of idrabiotaparinux or idraparinux.
Anti-Factor Xa activity was measured just prior to the infusion, just after the infusion, and then every day for five days to ensure that the reversibility remained unchanged.
The study found that there was less clinically relevant bleeding (5.2 percent versus 7.3 percent) and less major bleeding (0.8 percent versus 3.8 percent) in those treated with idrabiotaparinux as compared with idraparinux. Rates of recurrent venous thromboembolism (2.3 percent versus 3.2 percent) and fatal or non-fatal pulmonary embolism (1.6 percent versus 1.8 percent) were similar with both idrabiotaparinux and idraparinux.
Levels of Factor Xa activity were identical in both treatment groups throughout the six-month study. Of the 52 idrabiotaparinux patients re-randomized to receive avadin or placebo, 41 were analyzed for reversal of Factor Xa activity (23 received avidin and 18 received placebo). At the end of the 30-minute infusion of avidin, mean anti-Factor Xa activity was reduced by 77.8 percent and was sustained for at least five days as compared with 2.4 percent for the placebo group. The infusion of avidin was well-tolerated with no allergic reactions observed.
Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared With Warfarin in Subjects With Non-Valvular Atrial Fibrillation [Abstract #33]
Jeffrey I. Weitz, MD, Henderson Research Centre, Hamilton, Canada
The primary objective of this study was to evaluate the safety of four dosing regimens of DU-176b in patients with non-valvular atrial fibrillation. This phase II study found that two regimens (30 mg and 60 mg once-daily) of an investigational oral Factor Xa inhibitor, DU-176b, are safe in patients with non-valvular atrial fibrillation, making the drug a potential substitute for warfarin, the conventional blood-thinning agent used in such patients to prevent stroke.
Dosing of warfarin is complicated because it interacts with many commonly-used medications and even certain foods. For that reason, patients receiving warfarin require regular blood testing to monitor the international normalized ratio (INR) to ensure that an adequate yet safe dose of warfarin is given.
A total of 1,146 patients with atrial fibrillation were randomized to receive either one of four fixed-dose regimens of DU-176b (30 mg once-daily, 30 mg twice-daily, 60 mg once-daily, 60 mg twice-daily) or warfarin (dose-adjusted to a target INR of 2.0 to 3.0) for 12 weeks. The primary endpoints of the study were the incidence of bleeding events (major and clinically relevant non-major) and elevated liver enzymes and/or bilirubin, which might be indicative of hepatic toxicity. Secondary endpoints included major adverse cardiovascular events, stroke, systemic embolism, acute myocardial infarction, hospitalizations due to cardiovascular conditions, or cardiovascular death.
The incidence of major and clinically relevant non-major bleeding events was significantly higher in the 30 mg and 60 mg twice-daily DU-176b regimens than it was in patients given warfarin (7.8 percent, 10.6 percent and 3.2 percent, respectively). In contrast, the incidence of major and clinically relevant non-major bleeding events with the 30 and 60 mg once-daily DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent, and 3.2 percent, respectively). There were no significant differences in patients with elevated liver enzymes or bilirubin across all treatment groups, and there were no significant differences in the rates of secondary endpoints.
Once-Daily Oral Rivaroxaban Compared With Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis After Total Knee Replacement: RECORD4 [Abstract #35]
Alexander G.G. Turpie, MD, McMaster University, Hamilton, Ontario, Canada
This study concluded that investigational rivaroxaban, an oral Factor Xa inhibitor, is more efficacious than a current standard of therapy, enoxaparin, for the prevention of venous thromboembolism following total knee replacement surgery without significantly increasing the risk of bleeding. Coupled with previous research that demonstrated that post-operative rivaroxaban was more effective than pre-operative enoxaparin in preventing deep-vein clotting, along with an easier method of administration (oral versus subcutaneous injection), this study may change the way physicians prevent serious blood clots in patients undergoing major orthopedic surgery.
In this study, a total of 3,148 patients were randomized to receive either once-daily oral rivaroxaban (10 mg) starting six to eight hours after surgery or twice-daily subcutaneous injections of enoxaparin beginning 12 to 24 hours after surgery for 10 to 14 days. Patients underwent mandatory, bilateral venography (X-ray of the vein) between days 11 and 15.
The primary endpoint of the study was the combined occurrences of deep-vein thrombosis, non-fatal pulmonary embolism, and all-cause mortality up to day 17. The main safety endpoint was major bleeding observed after one dose of the drug until two days after the end of treatment. Efficacy was determined first by a test for non-inferiority in the per-protocol population of 1,702 patients, followed by a test for superiority in the intention-to-treat population of 1,924 patients.
The results indicated that rivaroxaban significantly reduced the incidence of adverse events (the combination of blood clots and death) by 31 percent as compared with enoxaparin, with no significant increase in the rate of major bleeding events. Rivaroxaban and enoxaparin appeared equally effective at preventing major venous blood clots and pulmonary embolism.
American Society of Hematology
Certain conditions can elevate a person's risk of clotting, including atrial fibrillation (an abnormal heart rhythm), previous heart attack, long periods of inactivity, some medications, and genetic or disease-related factors. Treatment typically consists of anticoagulants that help prevent clots from forming, medications that dissolve blood clots, catheter-directed thrombolysis (a surgical procedure where clot-dissolving medication is directed toward the blood clot), and thrombectomy, the surgical removal of a blood clot. Recognizing the deadly impact blood-clotting disorders have on millions of Americans every year, the American Society of Hematology has developed a new resource, www.bloodthevitalconnection.org, to help educate the public about these and other common blood diseases.
A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study [Abstract #6]
Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy
This study is the largest to determine that the preventive use of an antithrombotic medication can reduce the incidence of thromboembolic events in patients with cancer. It is well known that patients with cancer who receive chemotherapy are at high risk for developing deadly blood clots, but few large studies have confirmed whether the preventive use of a blood-thinning medication can reduce these events.
This multicenter, placebo-controlled, clinical outcome-based study was designed to evaluate the efficacy of nadroparin, a low-molecular-weight heparin, for the preventive treatment of thromboembolic events in cancer patients receiving chemotherapy. The primary outcome of the study was the combined occurrence of clinically overt venous or arterial thromboembolic events (i.e., deep-vein thrombosis of the lower and upper limbs, visceral and cerebral venous thrombosis, pulmonary embolism, acute myocardial infarction, ischemic stroke, acute peripheral arterial thromboembolism, and unexplained death of possible thromboembolic origin). Major bleeding was the main safety parameter.
In this study, 1,166 patients with advanced lung (279), colon (235), breast (165), ovarian (143), stomach (98), rectal (87), pancreatic (53), head and neck (36), and other cancers (54) were randomized to one of two treatment arms: once-daily subcutaneous injections of nadroparin (3,000 IU) or placebo. Twice as many patients were enrolled into the nadroparin group than the placebo group. Treatment was started on the first day of the current cycle of chemotherapy and was maintained for the overall duration of chemotherapy treatment or up to a maximum of four months.
Only 16 of the 769 patients treated with nadroparin had a thromboembolic event (2.1 percent) compared with 15 of the 381 patients (3.9 percent) in the placebo group, a 47.2 percent reduction in the risk of developing a thromboembolic event for the patients in the treatment arm. The drug also appeared to be safe as only five patients in the nadroparin group (0.7 percent) experienced a major bleeding episode, and the incidence of minor bleeding in the treatment arm was similar to that of the placebo group.
Venous thromboembolism occurred 11 times in both the nadroparin and placebo groups. Fifteen of these events occurred in patients with lung cancer (4 percent in the nadroparin arm and 8.8 percent in the placebo arm). Patients with pancreatic cancer also experienced a high overall rate of thromboembolic events (7.5 percent). While this study confirms that nadroparin reduces the incidence of thromboembolic events in cancer patients receiving chemotherapy, because of the disproportionately higher incidence of events in lung and pancreatic cancer patients, further studies should focus on patients in these two high-risk populations.
Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep-Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin [Abstract #32]
Harry Roger Buller, MD, PhD, Academic Medical Center, Amsterdam, Netherlands
This clinical trial found that six months of treatment with idrabiotaparinux, an anticoagulant and indirect Factor Xa inhibitor that links indraparinux to biotin, showed comparable efficacy to idraparinux alone with a trend toward less bleeding in patients with deep-vein thrombosis. Additionally, an infusion of avidin after the last idrabiotaparinux treatment led to a rapid reversal of the anti-Factor Xa activity, or the anticoagulant effect of the drug, which was sustained for at least five days. This study builds on previous research that showed similar efficacy and safety between once-weekly subcutaneous injections of indaparinux with standard treatment (low-molecular-weight heparin followed by a vitamin K antagonist) in the treatment of deep-vein thrombosis.
A total of 757 patients with symptomatic and confirmed deep-vein thrombosis were randomized to receive weekly subcutaneous injections of 3 mg idrabiotaparinux (385 patients) or 2.5 mg idraparinux (370 patients) for six months. The primary objective of the study was to determine whether idrabiotaparinux works in a similar manner to idraparinux (i.e., bioequipotency). The secondary objective of the study was occurrence of clinically relevant bleeding, death, or symptomatic recurrent venous thromboemolism at the end of six months of therapy.
A final objective included the reversal of the anticoagulant effect of idrabiotaparinux, as there are medically relevant instances, such as prior to surgery, when there is the need to reverse the effects of an anticoagulant. The reversal of the anticoagulant effect was measured after a 30-minute intravenous infusion of avidin (100 mg), a hen egg protein that binds with biotin to reverse the Factor Xa inhibiting activity of idrabiotaparinux. At the end of the initial six-month treatment with idrabiotaparinux, a subset of patients was re-randomized to receive avidin (those in the idrabiotaparinux arm) or placebo (those in both the idrabiotaparinux and idraparinux arms to preserve blinding). Avidin or placebo was infused between two and five hours after the last injection of idrabiotaparinux or idraparinux.
Anti-Factor Xa activity was measured just prior to the infusion, just after the infusion, and then every day for five days to ensure that the reversibility remained unchanged.
The study found that there was less clinically relevant bleeding (5.2 percent versus 7.3 percent) and less major bleeding (0.8 percent versus 3.8 percent) in those treated with idrabiotaparinux as compared with idraparinux. Rates of recurrent venous thromboembolism (2.3 percent versus 3.2 percent) and fatal or non-fatal pulmonary embolism (1.6 percent versus 1.8 percent) were similar with both idrabiotaparinux and idraparinux.
Levels of Factor Xa activity were identical in both treatment groups throughout the six-month study. Of the 52 idrabiotaparinux patients re-randomized to receive avadin or placebo, 41 were analyzed for reversal of Factor Xa activity (23 received avidin and 18 received placebo). At the end of the 30-minute infusion of avidin, mean anti-Factor Xa activity was reduced by 77.8 percent and was sustained for at least five days as compared with 2.4 percent for the placebo group. The infusion of avidin was well-tolerated with no allergic reactions observed.
Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared With Warfarin in Subjects With Non-Valvular Atrial Fibrillation [Abstract #33]
Jeffrey I. Weitz, MD, Henderson Research Centre, Hamilton, Canada
The primary objective of this study was to evaluate the safety of four dosing regimens of DU-176b in patients with non-valvular atrial fibrillation. This phase II study found that two regimens (30 mg and 60 mg once-daily) of an investigational oral Factor Xa inhibitor, DU-176b, are safe in patients with non-valvular atrial fibrillation, making the drug a potential substitute for warfarin, the conventional blood-thinning agent used in such patients to prevent stroke.
Dosing of warfarin is complicated because it interacts with many commonly-used medications and even certain foods. For that reason, patients receiving warfarin require regular blood testing to monitor the international normalized ratio (INR) to ensure that an adequate yet safe dose of warfarin is given.
A total of 1,146 patients with atrial fibrillation were randomized to receive either one of four fixed-dose regimens of DU-176b (30 mg once-daily, 30 mg twice-daily, 60 mg once-daily, 60 mg twice-daily) or warfarin (dose-adjusted to a target INR of 2.0 to 3.0) for 12 weeks. The primary endpoints of the study were the incidence of bleeding events (major and clinically relevant non-major) and elevated liver enzymes and/or bilirubin, which might be indicative of hepatic toxicity. Secondary endpoints included major adverse cardiovascular events, stroke, systemic embolism, acute myocardial infarction, hospitalizations due to cardiovascular conditions, or cardiovascular death.
The incidence of major and clinically relevant non-major bleeding events was significantly higher in the 30 mg and 60 mg twice-daily DU-176b regimens than it was in patients given warfarin (7.8 percent, 10.6 percent and 3.2 percent, respectively). In contrast, the incidence of major and clinically relevant non-major bleeding events with the 30 and 60 mg once-daily DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent, and 3.2 percent, respectively). There were no significant differences in patients with elevated liver enzymes or bilirubin across all treatment groups, and there were no significant differences in the rates of secondary endpoints.
Once-Daily Oral Rivaroxaban Compared With Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis After Total Knee Replacement: RECORD4 [Abstract #35]
Alexander G.G. Turpie, MD, McMaster University, Hamilton, Ontario, Canada
This study concluded that investigational rivaroxaban, an oral Factor Xa inhibitor, is more efficacious than a current standard of therapy, enoxaparin, for the prevention of venous thromboembolism following total knee replacement surgery without significantly increasing the risk of bleeding. Coupled with previous research that demonstrated that post-operative rivaroxaban was more effective than pre-operative enoxaparin in preventing deep-vein clotting, along with an easier method of administration (oral versus subcutaneous injection), this study may change the way physicians prevent serious blood clots in patients undergoing major orthopedic surgery.
In this study, a total of 3,148 patients were randomized to receive either once-daily oral rivaroxaban (10 mg) starting six to eight hours after surgery or twice-daily subcutaneous injections of enoxaparin beginning 12 to 24 hours after surgery for 10 to 14 days. Patients underwent mandatory, bilateral venography (X-ray of the vein) between days 11 and 15.
The primary endpoint of the study was the combined occurrences of deep-vein thrombosis, non-fatal pulmonary embolism, and all-cause mortality up to day 17. The main safety endpoint was major bleeding observed after one dose of the drug until two days after the end of treatment. Efficacy was determined first by a test for non-inferiority in the per-protocol population of 1,702 patients, followed by a test for superiority in the intention-to-treat population of 1,924 patients.
The results indicated that rivaroxaban significantly reduced the incidence of adverse events (the combination of blood clots and death) by 31 percent as compared with enoxaparin, with no significant increase in the rate of major bleeding events. Rivaroxaban and enoxaparin appeared equally effective at preventing major venous blood clots and pulmonary embolism.
American Society of Hematology
Deep-vein Thrombosis Current Events and Deep-vein Thrombosis News RSSScientists Find New No-Needle Approach to Prevent Blood Clots
The dean of the University of Oklahoma College of Public Health and a team of scientists worldwide have found a better way to prevent deadly blood clots after joint replacement surgery - a major problem that results in thousands of unnecessary deaths each year. The research appears this week in the New England Journal of Medicine.
AJN study reveals compression stockings incorrectly used in 29 percent of patients
An original study, published in the September issue of the American Journal of Nursing (AJN), revealed that graduated compression stockings were used incorrectly in 29% of the patients and sized incorrectly in 26% of the patients.
Damaged veins heal faster with heparin treatment, laboratory study finds
A commonly used medication that prevents blood clots from forming may also prevent existing clots from damaging delicate vein walls - and may accelerate healing in a clot-damaged area of vein wall, according to new research from the University of Michigan Cardiovascular Center.
Long-term estrogen therapy linked to breast cancer risk
Long-term estrogen therapy may be related to a higher risk of breast cancer among postmenopausal women who have had a hysterectomy, according to an article in the May 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
DVT Risk From Air Travel Unrelated To Reduced Air Pressure In Cabin (p 2207)
Results of a study published as a research letter in this week's issue of THE LANCET suggest that reduced air pressure (leading to decreased oxygen availability) in pressurised aircraft cabins is not associated with increased activity of the agents responsible for blood clotting and potential deep-vein thrombosis (DVT). The risk of venous thrombosis may be increased during aeroplane flights, possibly related to the activation of coagulation by low oxygen concentration (hypoxia) that is caused by the reduction of pressure in the aircraft cabin. Peter Robbins from the University of Oxford, UK, and colleagues exposed eight healthy human participants to eight hours of hypoxia and eight hours of
NEW SYNTHETIC ANTITHROMBOTIC DRUG COULD REDUCE DVT RISK AFTER HIP SURGERY (pp 1710, 1715, 1721)
Two studies in this week's issue of THE LANCET highlight how a new class of synthetic antithrombotic drug could be more effective than conventional therapy in reducing the risk of potentially fatal blood clots associated with hip-replacement surgery. Between 16 and 30% of patients who undergo Hip-replacement surgery have a risk of developing deep-vein thrombosis (DVT)-even when anti-clotting agents such as heparin and warfarin are used. DVT from hip surgery can occasionally result in death due to pulmonary embolism (in around 0.1-0.4% of cases). Michael Rud Lassen from University Hospital Copenhagen, Hiller'¸d, Denmark, and colleagues assessed the ability of fondaparinux, t
Infliximab Could Prevent Sight Loss From Behcet's Disease (p 295)
A drug used to treat rheumatoid arthritis and Crohn's disease could play an important role in preventing sight loss associated with the inflammatory disorder Behcet's disease, suggest authors of a fast-track research letter published in this week's issue of THE LANCET. Beh'§et's disease is a rare condition (although with increased incidence in mediterranean countries) affecting the small blood vessels which can cause deep-vein thrombosis, arthritis, oral and genital ulceration, skin lesions, central nervous system dysfunction, and retinal damage. Despite intensive immunosuppressive therapy, relapsing ocular inflammation, which occurs in about 70 % of cases, can lead to permanent blindness.
LINK BETWEEN DEEP-VEIN THROMBOSIS AND LONG-HAUL AIR TRAVEL STILL IN DOUBT (pp 1461, 1485)
Results of the first prospective randomised controlled trial to assess the effects of long-haul air travel and the risk of symptomless deep-vein thrombosis (DVT) are detailed in this week's issue of THE LANCET. Authors of an accompanying Commentary article conclude that the study does not resolve the long-standing controversy of the assumed association between DVT and air travel, and state that more research in this area is required. The frequency of clinically important DVT during long-haul air travel is unknown. New research into so-called 'economy-class syndrome', by John Scurr and colleagues from University College London, UK, has been the subject of considerable media speculation over t
More Deep-vein Thrombosis Current Events and Deep-vein Thrombosis News Articles
 |
100 Q&A About Deep Vein Thrombosis and Pulmonary Embolism (100 Questions & Answers about . . .) by Andra H. James (Author) Nearly two million Americans are affected annually by deep vein thrombosis. Whether you're a newly diagnosed patient, or a loved one of someone suffering from this disease, this book offers help. The only text available to provide both the doctor's and patient's views, 100 Questions & Answers About Deep Vein Thrombosis and Pulmonary Embolism gives you authoritative, practical answers to your questions. Written by two prominent physicians , Drs. James and Ortel, with "insider" advice from actual patients, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this condition. |
 |
Understanding DVT - Deep Vein Thrombosis Part of the award winning public television series Healthy Body/Healthy Min. A deep vein thrombosis is a blood clot that develops in a deep vein, usually in the leg. DVT is a very common condition, which affects about 2 million Americans every year. Certain genetic risk factors as well as acquired risk factors make a DVT more likely to occur. If a deep vein thrombosis is suspected, tests will be needed to confirm the diagnosis. But DVT can lead to a life threatening condition, called Pulmonary Embolism, a blood clot in the lungs. See how DVT can be detected and treated early, and how Pulmonary Embolism can be avoided. |
 |
Deep Vein Thrombosis Anatomical Chart Laminated-8953PL1.5 by Anatomical Chart Company |
 |
TravelSoft Padded Compression Sock (Large:M10-13, Black) by TravelSox The only compression sock with a padded foot bed. So comfortable you will want to wear them everyday! Offered in 3 sizes and two colors. |
 |
Avoid Deep Vein Thrombosis Self Hypnosis CD (Audio) by Steve G. Jones, M. Ed. Remaining in one position for too long a period causes deep Vein Thrombosis (DVT). The blood pools in one area, clotting up and then eventually moving into the heart, lungs or brain causing life-threatening damage. In today's busy world, it can be hard to remember to get up and move around every half hour. AVOID DEEP VEIN THROMBOSIS helps. *** By tapping into the subconscious, your body remembers to move around every now and then eliminating the potential for DVT. ** This audio program delivers the most powerful hypnosis program available without a prescription by internationally acclaimed Clinical Hypnotherapist Steve G. Jones . With this audio program, you will be getting the same powerful clinical hypnosis sessions that Steve G. Jones provides to Hollywood actors and corporate... |
 |
Understanding DVT - Deep Vein Thrombosis Directed By: (c) Information Television Network |
 |
Deep Vein Thrombosis Anatomical Chart Unmounted by Anatomical Chart Company |
 |
Deep Vein Thrombosis Photomic Photographic Poster Print, 24x18 by AllPosters.com AllPosters.com is the world's #1 seller of posters, prints, photographs, specialty products and framed art. We're dedicated to bringing our customers the best selection of high quality wall décor that is perfect for their home or office. Browse our catalog of over 300,000 items that include entertainment and specialty posters, decorative prints, and art reproductions. Whether you're looking for your favorite movie or music poster, a framed Monet reproduction, or a print of the Eiffel Tower you will find it at AllPosters.com. Visit our Amazon store today at www.amazon.com/allposters to find Special Offers and search by subject category or artist. AllPosters.com provides unmatched service with a 100% satisfaction guarantee. We ship internationally to over 80 countries. Decorate your... |
 |
Deep Vein Thrombosis Signal 12 (Primary Contributor) |
|
Diagnosis and Treatment of Deep Vein Thrombosis (CME Video for Primary Care Physicians) Also With: IMS (Primary Contributor) |
| © 2009 BrightSurf.com |